Company valuation ยท Basic Materials

NGVT: Hold with a $64.22 price target

Ingevity Corp. The company returned to profit, but the profit margin narrowed.

Model target ยท USD
$64.22
For 2027-09-16
Model rating
Hold
Reviewed 2026-09-16
Reference weekly close
$69.41
2026-09-11 ยท USD
Editorial illustration of Ingevity Corp, Specialty Chemicals.
Generated editorial illustration for Sharemaestro. It does not depict verified company premises or events.

Investment view

The company returned to profit, but the profit margin narrowed.

Target and reference price

Target for 2027-09-16: $64.22 USD, -7.5% versus the $69.41 weekly close on 2026-09-11. Price return only; dividends, fees and tax excluded.

Price and earnings

Over 1 year (2025-09-12 to 2026-09-11), price changed +19.4% and trailing EPS changed +9.0%. A wider gap changes the earnings multiple; it does not establish fair value.

Supporting evidence

Net income was 35.3m, compared with -146.5m in the same quarter last year. Amounts are in USD.

Cash after capital spending / profit: 2.9ร— for NGVT, against 0.9ร— across 9 comparable peers.

Risks to the case

The latest quarterly operating margin was 19.1%, -6.8 percentage points from a year earlier. The full report separates sales growth from margin changes.

Revenue changed -5.2% from the same quarter last year, through 2026-06-30. The previous quarterโ€™s year-on-year change was +4.1%.

What to monitor

The latest quarterly margin changed -6.8 percentage points from a year earlier. Check sales volumes, pricing and unusual gains in the next filing.

Recheck the valuation gap alongside profitability and growth after new results. A discount alone does not establish value.

Compare the stock and the market fund over the same dates. Look for a change in relative performance as results arrive.

Valuation assumptions

Starting annual sales growth: -1.66%.

Long-term operating margin: 32.58%.

About this assessment

Review recorded on 2026-09-16. This is a dated summary of an automated company valuation. The full report includes the financial evidence, alternative scenarios and review history. Consult the latest report before using an earlier target. Automated model research, not personal investment advice. Targets depend on assumptions; returns are not guaranteed.

Evidence context